Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PRIMO 2023 | Recent advances in the management of pancreatic cancer

Andrew Ko, MD, FASCO, University of California, San Francisco, CA, discusses developments in the treatment of pancreatic cancer, including findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Dr Ko also talks on the future role of targeted therapies such as sotorasib and adagrasib in KRAS G12C-mutant pancreatic cancer, and immunotherapy. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.